Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
Holzgreve, Adrien, Unterrainer, Marcus, Calais, Jérémie, Adams, Thaiza, Oprea-Lager, Daniela E., Goffin, Karolien, Lopci, Egesta, Unterrainer, Lena M., Kramer, Kristina K. M., Schmidt-Hegemann, Nina-Sophie, Casuscelli, Jozefina, Stief, Christian G., Ricke, Jens, Bartenstein, Peter, Kunz, Wolfgang G., Mehrens, Dirk
Published in European journal of nuclear medicine and molecular imaging (01.10.2023)
Published in European journal of nuclear medicine and molecular imaging (01.10.2023)
Get full text
Journal Article
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Mehrens, Dirk, Kramer, Kristina K M, Unterrainer, Lena M, Beyer, Leonie, Bartenstein, Peter, Froelich, Matthias F, Tollens, Fabian, Ricke, Jens, Rübenthaler, Johannes, Schmidt-Hegemann, Nina-Sophie, Herlemann, Annika, Unterrainer, Marcus, Kunz, Wolfgang G
Published in Journal of the National Comprehensive Cancer Network (01.01.2023)
Published in Journal of the National Comprehensive Cancer Network (01.01.2023)
Get more information
Journal Article